Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Summary not available.
Summary not available.
Illumina announced a strategic research collaboration with AstraZeneca on October 11, 2022, aimed at accelerating drug target discovery by leveraging AI capabilities and genomic analysis. The partnership seeks to combine Illumina's AI-based tools with AstraZeneca's frameworks to enhance the precision of drug candidate identification. Joydeep Goswami highlighted the potential to prioritize candidates with higher approval prospects. The initiative focuses on analyzing multi-omics data and could pave the way for a long-term partnership based on its success.
Illumina (NASDAQ: ILMN) will release its third quarter 2022 financial results on November 3, 2022, after market close. The conference call for discussion will occur at 2:00 PM PT (5:00 PM ET) on the same day, hosted by CEO Francis deSouza and Interim CFO Joydeep Goswami. Investors can access the call via Illumina's investor website or by phone. A replay will be available for at least 30 days post-event. Illumina continues to lead in DNA sequencing and array-based technologies, supporting various health science applications.
Illumina (NASDAQ: ILMN) introduced several groundbreaking sequencing technologies at the inaugural Illumina Genomics Forum in San Diego on Sept. 29, 2022. Key innovations include the NovaSeq™ 6000 Dx, the first FDA-registered high-throughput sequencer, enhancing patient care by increasing access to clinical genomics. The NovaSeq X Series can generate over 20,000 whole genomes annually, tripling throughput and minimizing environmental impact. The XLEAP-SBS™ Chemistry offers faster and more accurate sequencing, while upcoming products promise improved throughput and cost-efficiency in genomic research.
Illumina, a leader in DNA sequencing, announced the launch of the NovaSeq X Series, capable of sequencing over 20,000 genomes annually, which is 2.5 times more than previous models. This high-throughput sequencer promises reduced operational costs and enhanced accuracy through innovative technologies like XLEAP-SBS™ chemistry and ultra-high-density flow cells. In addition, the NovaSeq X features sustainable practices, achieving a 90% reduction in packaging waste and eliminating dry ice shipments. This advancement aims to transform genomics and improve healthcare outcomes globally.
Illumina announced its inaugural Genomics Forum, taking place in San Diego from September 28 to October 1, is officially sold out. To cater to increased interest, the company will host an Innovation Roadmap session on September 29, featuring CEO Francis deSouza and Chief Technology Officer Alex Aravanis, available via livestream. The forum will include over 70 speakers from diverse fields, highlighting notable figures like former President Barack Obama and Bill Gates.
Henry Ford Health has become the first healthcare provider in Michigan to offer the Galleri Multi-Cancer Early Detection (MCED) blood test. This groundbreaking test can detect cancer signals from over 50 types of cancer through a single blood draw, significantly enhancing early diagnosis capabilities. Aimed primarily at individuals aged 50 and older, the test also accommodates younger patients without cancer history. While promising, the test requires out-of-pocket payment as it is not yet covered by insurance. Initial studies indicate its effectiveness in identifying cancers not typically screened.
John Hancock announced it will offer the Galleri multi-cancer early detection test to a pilot group of existing customers via the John Hancock Vitality Program. This collaboration with Munich Re Life US marks the first time a life insurer has made such technology accessible. The Galleri test can identify signals from over 50 types of cancer, supporting early diagnosis and better health outcomes. Participation in this pilot will help assess customer uptake and experience, while ensuring individual results remain confidential and do not affect insurance coverage.
Illumina will host its 2022 Investor Day on October 3, 2022, at 8:00 am PT in San Diego, CA. The event will include presentations from Illumina's executive team, followed by a Q&A session. Interested parties can access a live webcast via the Investor Info section of Illumina's website. A replay will also be available for 30 days post-event. Illumina is a leader in DNA sequencing technologies, impacting various fields including life sciences and oncology.